Kjell G Stenberg
Kjell Stenberg, PhD served as Chief Operating Officer of Medwell Capital Corp. (also known as BioMS Medical Corp. developing a new drug in phase III studies for MS. In 2008 BioMS entered into a partnership with Eli Lilly that was awarded Licensing Deal Of the Year by Scrips. Previously, Dr. Stenberg served as Chief Executive Officer of Combio A/S. From 1975 to 2000, Dr. Stenberg served as Senior Researcher and Manager at Astra/AstraZeneca, where he was instrumental in bringing various drugs to market in the capacity of Director of Research or Director of Development. He is Chairman of Aptahem AB and board member of Novation Pharmacuticals and Galecto Biotech.
Master of business and economics with many years of experience as CFO and working with start-ups and growth projects within the private as well as with state and regional development actors.